Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Randy Schmid who wrote (2015)	10/2/1997 5:45:00 PM
From: H. Bradley Toland, Jr.	of 6136

Randy: Regarding the tax loss carryforward they did not use it up for tax purposes, but they did recognize the loss carryforward as an asset for financial reporting at June 30, 1997 because they were now profitable. This is generally accepted accounting and they will report "fully taxed" earnings going forward but on their tax return they will pay "0" in cash until the loss carryforward is used up. The "tax asset" will dimishish commensurately. Regarding Thymitaq the only comment I heard from the company was that patient accruals took longer than they had expected when the current trial began. I have no information about FDA input. I have one general comment as well, similar to an earlier comment. Even though Viracept is key to the near term valuation of the company for those with a multi-year time horizon the real story here is the large number of product candidates and what appears to be an exceptionally productive scientific effort. Three cancer drugs in human clinical trials and a protease inhibitor for cold virus, among many others is what intriques me.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next